IONIS-FB-LRx

DRUG3 trials

Sponsors

Ionis Pharmaceuticals, Inc.

Conditions

Age Related Macular DegenerationGeographic AtrophyMacular DegenerationPrimary IgA Nephropathy

Phase 2

Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

WithdrawnNCT03446144

Ionis Pharmaceuticals, Inc.Age Related Macular Degeneration, Geographic Atrophy

Start: 2018-03-16End: 2018-10-10Updated: 2019-08-13

GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

CompletedNCT03815825

Ionis Pharmaceuticals, Inc.Geographic Atrophy, Macular Degeneration

Start: 2019-03-04End: 2024-06-12Updated: 2025-03-07

A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy

CompletedNCT04014335

Ionis Pharmaceuticals, Inc.Primary IgA Nephropathy

Start: 2019-12-04End: 2024-04-11Updated: 2025-01-23

Related Papers

A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy.

2025-12-22

#3089 Suppression of complement alternative pathway by monthly dosing of sefaxersen, a novel antisense oligonucleotide therapy in development for IgAN

Nephrology Dialysis Transplantation2025-10-01

#388 IONIS-FB-LRx, an antisense oligonucleotide to complement factor B for treatment of IgA nephropathy

Nephrology Dialysis Transplantation2024-05-017 citations